More or Less Irregularity in Understanding an Irregular Rhythm: Atrial Fibrillation Classification and Racial Differences

Elsayed Z. Soliman, MD, MSc, MS, FAHA, FACC

The past few years have witnessed unprecedented advances in the field of atrial fibrillation (AF) research. This includes developing new AF risk prediction models,1–3 introducing safer anticoagulants,4–6 and identifying several novel AF risk factors.7 Despite these great advances, however, we still do not have a full understanding of some of the basic concepts about this common arrhythmia that affects over 2 million people in the United States—a number that is expected to double in the next few decades.8 AF is a complex disease with a multifactorial etiology and far-reaching complications. Although we may now know several traditional and novel AF risk factors, it is not entirely clear how they interact with each other under different predispositions to AF. This lack of holistic understanding of exactly how and why AF develops makes this irregular cardiac rhythm difficult to understand or even describe.

In this issue of JAHA, there are 2 separate articles in which the authors sought to address some of the irregularities in understanding the epidemiology of AF. In one article Lubitz et al9 address the classification of AF patterns in longitudinal studies, and in another article Thomas et al10 address the racial differences in the prevalence of AF.

Classification of AF Patterns
The current recommended classification of AF patterns by the American College of Cardiology (ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC) is based on the timing of detection, method of conversion to sinus rhythm, whether self-terminating or induced, recurrence, and duration of AF.11 AF is classified as “first-detected” if diagnosed in individuals who have no history of this arrhythmia. AF that recurs after the first-detected episode is considered “paroxysmal” if it self-terminates within 1 week, “persistent” if it continues beyond this period and is not self-terminating, or “permanent” if efforts to terminate the rhythm fail or are not attempted. This classification scheme represents a consensus driven by a desire for simplicity and clinical relevance.11 As could be imagined, patients could be moving from one AF pattern to another based on the natural history of the disease or intervening treatment. Even cases with permanent AF could change label to be persistent AF if an intervention (eg, catheter ablation) is successfully applied at a later stage. Hence, it may not be always simple to consistently classify AF using the ACC/AHA/ESC classification scheme, and subsequently it may not be always feasible to examine or compare the clinical relevance of different AF patterns since we cannot identify each pattern precisely and consistently in the first place.

In the clinical setting, the main purpose of giving a certain label to an AF pattern is to rationalize the need for a specific treatment option(s) at the time the patient is seen. Since changes are expected in patients’ conditions and subsequent treatment plans even in the short-term, having different labels for AF at different times should not pose significant challenges in patient care. In this context, the recommended ACC/AHA/ESC AF classification fulfills its purpose as part of patient care. However, it may not be ideal in the research setting, especially in long-term population studies where using a highly reproducible easy-to-apply method for AF classification is critical. With most of our evidence-based knowledge obtained from large population studies, using an AF classification that fits both clinical and research settings is needed. The article by Lubitz et al9 published in this issue of JAHA is a significant step toward this aim.

Using data from the Framingham Heart Study, Lubitz et al9 proposed using a fixed 2-year time window to classify AF into 3 patterns: AF without recurrence, recurrent AF, and sustained AF. Compared with individuals without 2-year AF
recurrences, the authors showed that the 10-year prognosis was worse for individuals with either sustained or recurrent AF. The simplicity of this proposed classification makes it likely to be reproducible in the research setting. Similarly, its ability to separate participants according to their levels of risk makes it a useful clinical tool as well. However, whether the 2-year window for classification of AF patterns, as proposed by Lubitz et al., is the ideal time window compared to other time windows is not clear at this stage. Also, several paroxysmal AF episodes can go undetected unless long-term rhythm monitoring is applied, and hence not detecting AF on a routine resting 12-lead electrocardiogram (ECG) does not mean that the patient really has no AF (or recurrent AF). This could lead to misclassification of “AF without recurrence” in the proposed classification. Regardless of this limitation, which is expected to be affecting any AF classification, the proposed classification by Lubitz et al. should lessen some of the challenges in classifying AF in longitudinal studies by using a simple potentially reproducible approach.

Atrial Fibrillation in Blacks

The prevalence and incidence of AF have been repeatedly shown to differ by race, with blacks having more AF, and finally differential impact of AF risk factors with whites being more affected or blacks less affected by AF risk factors whether this is genetically determined or via other unknown predispositions. A most of these possibilities have been tested and proved not to provide convincing explanation for the paradox of AF in blacks. This is with the exception of thoroughly examining the hypothesis that blacks might have more AF patterns that are harder to detect because of their intermittent nature such as paroxysmal AF or atrial flutter, which require long-term rhythm monitoring to detect. Implementation of long-term rhythm monitoring in population studies has been traditionally challenged by logistics and cost. Nevertheless, with the new generations of small long-term rhythm recording and monitoring devices, this may be the time to test this hypothesis.

In summary, despite the great progress in AF research, we still need to straighten out some of the irregularities in our basic understanding of this irregular rhythm. This includes the need to explain the paradoxical associations of AF with race that defy logic, as well as coming up with a better way for classifying AF that is appropriate in both clinical and research settings. In this regard, the studies by Lubitz et al.9 and Thomas et al.10 could be seen as either steps toward less irregularity in understanding AF or examples of the challenges we face in understanding this common cardiac rhythm disorder. What is sure, however, is that with the increasing life expectancy and aging of the US population, having more research in an age-related disease such as AF is really needed and worth investing.

Disclosures

None.

References

1. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D’Agostino RB Sr, Neaton JD, O’Donnell C, Yamamoto JF, Magnani JW, Tadros TM, Kannel WB, Wang TJ, Ellinor PT, Wolf PA, Vasan RS, Benjamin EJ. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009;373:739–745.

2. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, Sinner MF, Sotoodehnia N, Fontes JS, Janssens AC, Kronmal RA, Magnani JW, Wittman JC, Chamberlain AM, Lubitz SA, Schnabel RB, Agarwal SK, McManus DD, Ellinor PT, Larson MG, Burke GL, Launer LJ, Hofman A, Levy D, Gottdiener JS, Kääb S, Couper D, Harris TB, Soliman EZ, Stricker BH, Gudnason V, Heckbert SR, Benjamin EJ. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2:e000102. doi:10.1161/JAHA.112.000102.

3. Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R, Ambrose M, Alonso A. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011;107:85–91.

4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccioni JP, Becker RC, Nessel CC, Paolino JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.

5. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JJ, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hemosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE

DOI: 10.1161/JAHA.113.000482
Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.

6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.

7. Rienstra M, McManus DD, Benjamin EJ. Novel risk factors for atrial fibrillation: useful for risk prediction and clinical decision making? Circulation. 2012;125:e941–e946.

8. Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370–2375.

9. Lubitz SA, Moser C, Sullivan L, Rienstra M, Fontes JD, Villalon ML, Pai M, McManus DD, Schnabel RB, Magnani JW, Yin X, Levy D, Pencina MJ, Larson MG, Ellinor PT, Benjamin EJ. Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. J Am Heart Assoc. 2013;2:e000126 doi:10.1161/JAHA.113.000126.

10. Thomas KL, Piccini JP, Liang L, Fonarow GC, Yancy CW, Peterson ED, Hernandez AF; for the Get With the Guidelines Steering Committee and Hospitals. Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure. J Am Heart Assoc. 2013;2:e000200 doi: 10.1161/JAHA.113.000200.

11. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC Jr, Priori SG, Estes NA III, Ezekowitz MD, Jackman WM, January CT, Page RL, Slootwier DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Hochman JS, Kusner FG, Ohman EM, Tarkington LG, Yancy CW. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:e269–e367.

12. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455–2461.

13. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Primeas RJ, Folsom AR. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158:111–117.

14. Ruo B, Capra AM, Jensvold NG, Go AS. Racial variation in the prevalence of atrial fibrillation among patients with heart failure. J Am Coll Cardiol. 2004;43:429–435.

15. Borzechki AM, Bridges DK, Liebschutz JM, Kader B, Kazis LE, Berlowitz DR. Racial differences in the prevalence of atrial fibrillation among males. J Natl Med Assoc. 2008;100:237–246.

16. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Macleod R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:1501–1508.

17. Kissela B, Schneider A, Kleindorfer D, Khoury J, Miller R, Alwell K, Woo D, Szafarski J, Gelles J, Moomaw C, Pancioli A, Jauch E, Shukla R, Broderick J. Stroke in a biracial population: the excess burden of stroke among blacks. Stroke. 2004;35:426–431.

18. White H, Boden-Albala B, Wang C, Elkind MS, Rundek T, Wright CB, Sacco RL. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation. 2005;111:1327–1331.

19. Soliman EZ, Alonso A, Goff DC Jr. Atrial fibrillation and ethnicity: the known, the unknown and the paradox. Future Cardiol. 2009;5:547–556.

Key Words: Editorials • atrial fibrillation